Wegovy®

Coverage varies dramatically by plan. Many commercial insurers cover Wegovy with prior authorization when you meet the BMI criteria, and Medicare Part D may cover it under the 2024 cardiovascular indication. Our team helps run a benefits check and submit prior authorization if needed.

The active molecule is identical. Wegovy is FDA-approved, manufactured by Novo Nordisk, and delivered in pre-measured pens. Compounded semaglutide is mixed by a state-licensed 503A pharmacy, typically uses vial-and-syringe dosing, and is usually less expensive cash-pay. Outcomes are comparable when dosing is matched.

You have three paths: appeal the denial with clinical documentation we provide, enroll in Novo Nordisk’s NovoCare direct-pay program at roughly $499 per month, or discuss switching to compounded semaglutide where appropriate. Your doctor will walk through the tradeoffs with you.

Most patients see early appetite changes within 2–3 weeks of starting the 0.25 mg titration dose. Meaningful scale movement typically begins around weeks 8–12 as you climb to higher strengths. STEP 1 trial participants averaged about 15% body-weight loss at 68 weeks on the 2.4 mg maintenance dose.

Yes. Because the molecule is identical, your doctor can transition you in either direction without re-titrating from zero in most cases — they will match your current effective dose to the closest Wegovy pen strength. Many patients switch when insurance approves Wegovy, or back to compounded if coverage is denied.

Ozempic is the same molecule approved for type 2 diabetes; Wegovy is approved for weight management and CV risk reduction. Insurance often dictates the choice — diabetes coverage typically routes patients to Ozempic, while obesity coverage routes to Wegovy. Your doctor will recommend based on your indication and benefits.

No. The FDA formally resolved the Wegovy shortage in mid-2024, and all five pen strengths are now reliably available. This also means compounded semaglutide no longer qualifies under the chronic-shortage exemption pathway, though state-licensed 503A compounding remains available under patient-specific clinical criteria.

Yes — same molecule, same 2.4 mg dose, same pen. The FDA expanded the label in March 2024 based on the SELECT trial, which showed about a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease. No formulation change was involved.